This site is intended only for the use of Canadian Healthcare Professionals

Choose language:

Open Search
Open Menu

Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies (2024)

The aim of this 2024 review was to provide the most contemporary evidence addressing changes in lean body mass and muscle composition with GLP-1-based therapies, along with current and developing mitigation strategies. The review focused on the complex relationship between muscle quantity, composition, function, and metabolic physiology, and the impacts of GLP-1-based treatments. It also addressed the challenges and opportunities in assessing and improving muscle health and sarcopenia during weight loss.

Neeland IJ, Linge J, Birkenfeld AL.Changes in lean body mass with glucagon-likepeptide-1-based therapies and mitigation strategies. DiabetesObes Metab. 2024;26(Suppl. 4):16‐27. doi:10.1111/dom.15728.

This site is intended only for Canadian healthcare professionals. The products discussed in this site may have different product labeling in different countries.
In the event of a discrepancy between website information and product packaging, please refer to product packaging.
The information provided is for educational purposes only.

All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland and used under license. ©2023 Nestlé.